These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Recommendations for the evaluation of possible therapeutic effects of blood purification methods in chronic schizophrenic patients. Hippius H; Matussek N; Nedopil N; Strauss A; von Zerssen GD; Emrich H; Kolff WJ; Gurland HJ Neuropsychobiology; 1980; 6(3):140-4. PubMed ID: 6103520 [No Abstract] [Full Text] [Related]
44. [A controlled study of a thymoanaleptic drug (nialamide) in stabilized schizophrenics]. Sutter JM; Luccioni H; Scotto JC; Begarra R Act Nerv Super (Praha); 1968 Oct; 10(3):245-50. PubMed ID: 4883235 [No Abstract] [Full Text] [Related]
45. Response to Kujawa et al. letter-to-the-editor. Sethuraman G; Taylor CC; Enerson M; Dunayevich E Schizophr Res; 2006 May; 84(1):172-3. PubMed ID: 16563702 [No Abstract] [Full Text] [Related]
46. Predicting individual responses to drug treatment in schizophrenia: a test dose model. May PR; Van Putten T; Yale C; Potepan P; Jenden DJ; Fairchild MD; Goldstein MJ; Dixon WJ J Nerv Ment Dis; 1976 Mar; 162(3):177-83. PubMed ID: 3623 [TBL] [Abstract][Full Text] [Related]
47. Darvon and Darvon-N. Med Lett Drugs Ther; 1972 May; 14(11):37-8. PubMed ID: 4567561 [No Abstract] [Full Text] [Related]
48. Chlordiazepoxide in the treatment of patients with "activated EEG's". Monroe RR; Dale R Dis Nerv Syst; 1967 Jun; 28(6):390-6. PubMed ID: 5340423 [No Abstract] [Full Text] [Related]
49. On-going national collaborative studies in Canada: niacin in the treatment of schizophrenias. Ban TA Psychopharmacol Bull; 1969 Jul; 5(3):5-20. PubMed ID: 4906584 [No Abstract] [Full Text] [Related]
50. Low dose maintenance medication for schizophrenia. Manchanda R; Hirsch SR Br Med J (Clin Res Ed); 1986 Aug; 293(6546):515-6. PubMed ID: 2875757 [No Abstract] [Full Text] [Related]
51. Clinical trial of triperidol. Chien C; DiMascio A; Ewalt JR Curr Ther Res Clin Exp; 1967 Nov; 9(11):544-50. PubMed ID: 4965502 [No Abstract] [Full Text] [Related]
52. Assessment of drugs in schizophrenia. Discussion on basic trial design. Coppen A Br J Clin Pharmacol; 1976 Jun; 3(3 Suppl 2):381-3. PubMed ID: 791325 [No Abstract] [Full Text] [Related]
53. Are medication-free periods necessary for phase 3 trials of new antipsychotic drugs? Volavka J Arch Gen Psychiatry; 1998 Mar; 55(3):280-1; 283. PubMed ID: 9510226 [No Abstract] [Full Text] [Related]
54. Tea drinking and neuroleptic dosage. Cheung HK Am J Psychiatry; 1981 Nov; 138(11):1517. PubMed ID: 6117206 [No Abstract] [Full Text] [Related]
55. How to manage the first episode of schizophrenia. Authors did not take account of systemically collected information. Crow TJ BMJ; 2001 Jan; 322(7280):234-5. PubMed ID: 11159635 [No Abstract] [Full Text] [Related]
56. Clinical trials for negative symptoms--emerging directions and unresolved issues. Marder SR; Rabinowitz J; Kapur S Schizophr Res; 2013 Nov; 150(2-3):327. PubMed ID: 24209763 [No Abstract] [Full Text] [Related]
57. Clinical observations on reserpine reversal after prolonged MAO inhibition. Esser AH Psychiatr Neurol Neurochir; 1967; 70(1):59-63. PubMed ID: 5339995 [No Abstract] [Full Text] [Related]
59. Schizophrenia drug shines in phase III. Kingwell K Nat Rev Drug Discov; 2022 Oct; 21(10):702. PubMed ID: 36045284 [No Abstract] [Full Text] [Related]
60. Evaluation of new drugs for schizophrenia. Sugerman AA J Med Soc N J; 1967 Sep; 64(9):513-7. PubMed ID: 4863837 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]